MedTrace Logo

Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure

NCT01543854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2014-08-05

No results posted yet for this study

Summary

This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart failure. In addition safety and effects on renal function and biomarkers will be assessed.

Conditions

  • Acute Heart Failure

Interventions

DRUG

RLX030

Intravenous infusion of RLX030 over 20 hrs

DRUG

Placebo

Intravenous infusion of placebo over 20 hours

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
87 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Argentina
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543854 on ClinicalTrials.gov